3rd Quarter - Termination Amendment
MYRIAD GENETIC LABORATORIES, INC. for MYRIAD GENETIC LABORATORIES, INC.
Income
—
Expenses
$160,000
Expense method
A: Lobbying Disclosure Act definitions
Terminated
Aug 31, 2018
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 3rd Quarter - Termination | Sep 4, 2018 | $180,000 | Replaced |
| 3rd Quarter - Termination Amendment (this page) | Oct 16, 2018 | $160,000 | Yes |
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Section 216(a) of the Protecting Access to Medicare Act of 2014 (PAMA) (Pub. L. 113- 93) - payment and coding for laboratory tests
| Lobbyist | Covered position, as disclosed |
|---|---|
| KIMBERLY LINTHICUM | Leg Director, Rep Bob Franks (1997-2000) Leg Correspondent, Rep Charles Taylor (1997) Leg Correspondent, Rep Bill Martini (1995-1996) |
Medical/Disease Research/Clinical Labs MED
Regulation of laboratory developed tests - discussion draft (no HR #) Diagnostic Accuracy and Innovation Act (DAIA)
| Lobbyist | Covered position, as disclosed |
|---|---|
| KIMBERLY LINTHICUM | Leg Director, Rep Bob Franks (1997-2000) Leg Correspondent, Rep Charles Taylor (1997) Leg Correspondent, Rep Bill Martini (1995-1996) |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.